Name: Aspire Biopharma Holdings, Inc. (ASBP) Financial Statements
Creator: FinSpry

Aspire Biopharma Holdings Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Aspire Biopharma Holdings, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022
Period Ending	Dec 2024	Dec 2023	Dec 2022
Revenue & Gross Profit
Revenue	0.00	0.00	0.00
Cost of Revenue	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00
Operating Expenses
Research & Development	0.14	0.07	0.18
Selling, General & Administrative	3.09	1.34	0.42
Operating Expenses	3.09	1.34	0.60
Operating Income	-3.09	-1.34	-0.60
Other Income/Expense
Interest Income	0.55	5.81	0.00
Interest Expense	-0.89	0.01	0.00
Other Income/Expense	-9.45	0.00	0.00
Income
Income Before Tax	-12.54	4.46	-0.60
Income Tax Expense	0.00	0.00	0.00
Net Income	-12.54	4.46	-0.60
Net Income - Continuous Operations	-12.54	4.46	-0.60
Net Income - Discontinued Operations	0.00	0.00	0.00
EBITDA	-11.65	4.47	-0.60
EBIT	-1.21	4.47	-0.60
Depreciation & Amortization	0.00	0.00	0.00
Earnings Per Share
Basic EPS	-	4.00	-1.00
Diluted EPS	-	4.00	-1.00
Basic Shares Outstanding	32.98	1.15	1.15
Diluted Shares Outstanding	32.98	1.15	1.15